A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
- PMID: 10402204
- DOI: 10.1016/s0896-6273(00)80764-3
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
Abstract
We have produced yeast artificial chromosome (YAC) transgenic mice expressing normal (YAC18) and mutant (YAC46 and YAC72) huntingtin (htt) in a developmental and tissue-specific manner identical to that observed in Huntington's disease (HD). YAC46 and YAC72 mice show early electrophysiological abnormalities, indicating cytoplasmic dysfunction prior to observed nuclear inclusions or neurodegeneration. By 12 months of age, YAC72 mice have a selective degeneration of medium spiny neurons in the lateral striatum associated with the translocation of N-terminal htt fragments to the nucleus. Neurodegeneration can be present in the absence of macro- or microaggregates, clearly showing that aggregates are not essential to initiation of neuronal death. These mice demonstrate that initial neuronal cytoplasmic toxicity is followed by cleavage of htt, nuclear translocation of htt N-terminal fragments, and selective neurodegeneration.
Similar articles
-
Huntington disease: new insights on the role of huntingtin cleavage.J Neural Transm Suppl. 2000;(58):1-17. doi: 10.1007/978-3-7091-6284-2_1. J Neural Transm Suppl. 2000. PMID: 11128600 Review.
-
Selective degeneration in YAC mouse models of Huntington disease.Brain Res Bull. 2007 Apr 30;72(2-3):124-31. doi: 10.1016/j.brainresbull.2006.10.018. Epub 2006 Nov 16. Brain Res Bull. 2007. PMID: 17352936 Review.
-
Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.Cell Death Differ. 2004 Apr;11(4):424-38. doi: 10.1038/sj.cdd.4401358. Cell Death Differ. 2004. PMID: 14713958
-
Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16. Neurobiol Dis. 2008. PMID: 18502655 Free PMC article.
-
Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.J Gene Med. 2012 Jul;14(7):468-81. doi: 10.1002/jgm.2641. J Gene Med. 2012. PMID: 22700462
Cited by
-
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.Neuron. 2012 Jun 21;74(6):1031-44. doi: 10.1016/j.neuron.2012.05.009. Neuron. 2012. PMID: 22726834 Free PMC article.
-
Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.J Neurol. 2006 Sep;253(9):1137-42. doi: 10.1007/s00415-006-0198-8. Epub 2006 Sep 22. J Neurol. 2006. PMID: 16998646 Review.
-
Structural Plasticity of the Hippocampus in Neurodegenerative Diseases.Int J Mol Sci. 2022 Mar 20;23(6):3349. doi: 10.3390/ijms23063349. Int J Mol Sci. 2022. PMID: 35328770 Free PMC article. Review.
-
Functional aspects of cellular microcompartmentation in the development of neurodegeneration: mutation induced aberrant protein-protein associations.Mol Cell Biochem. 2004 Jan-Feb;256-257(1-2):83-93. doi: 10.1023/b:mcbi.0000009860.86969.72. Mol Cell Biochem. 2004. PMID: 14977172 Review.
-
Anti-human placental antigen complex X-P2 (hPAX-P2) anti-serum recognizes C-terminus of huntingtin-associated protein 1A common to 1B as a determinant marker for the stigmoid body.Histochem Cell Biol. 2007 Oct;128(4):335-48. doi: 10.1007/s00418-007-0315-5. Epub 2007 Aug 9. Histochem Cell Biol. 2007. PMID: 17687563
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials